Key result
Irbesartan is an angiotensin II receptor blocker with high oral bioavailability that provides effective antihypertensive and renoprotective benefits for patients with hypertension and diabetic nephropathy.
Irbesartan is an established angiotensin II receptor blocker for the management of hypertension, particularly in patients with type 2 diabetes and impaired renal function.
Confirms irbesartan role in hypertension and diabetic nephropathy; leaves open optimal combinations versus newer agents.
Irbesartan belongs to a group of angiotensin II receptor blockers that are used worldwide for the treatment of patients with hypertension, type 2 diabetes, and impaired renal function. Irbesartan can be administered alone or in combination with other antihypertensive drugs (for example, hydrochlorothiazide), if blood pressure control cannot be achieved with monotherapy. The mechanism of action of Irbesartan is mainly due to the selective blockade of AT1 receptors and, as a consequence, a decrease in the vasopressor effect of angiotensin II. The review article summarizes pharmacokinetic and pharmacodynamic properties and clinical data on the tolerability and safety of Irbesartan.
No takes yet. Share an insight, caveat, or question.
Rebrova et al. (2022) conducted a review in Arterial hypertension and cardiovascular diseases. Irbesartan was evaluated. Irbesartan is an angiotensin II receptor blocker with high oral bioavailability that provides effective antihypertensive and renoprotective benefits for patients with hypertension and diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: